170 related articles for article (PubMed ID: 17082588)
21. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
22. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
24. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors.
Park SH; Kyin T; Bendelac A; Carnaud C
J Immunol; 2003 Feb; 170(3):1197-201. PubMed ID: 12538676
[TBL] [Abstract][Full Text] [Related]
25. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
26. Two distinct populations of primary cytotoxic cells infiltrating into allografted tumor rejection sites: infiltration of macrophages cytotoxic against allografted tumor precedes that of multiple sets of cytotoxic T lymphocytes with distinct specificity to alloantigens.
Yoshida R; Matsuura A; Einaga K; Ushio Y; Yamamoto N; Yoneda Y
Microbiol Immunol; 1997; 41(2):149-59. PubMed ID: 9087957
[TBL] [Abstract][Full Text] [Related]
27. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor.
Pilon SA; Kelly C; Wei WZ
J Immunol; 2003 Feb; 170(3):1202-8. PubMed ID: 12538677
[TBL] [Abstract][Full Text] [Related]
28. Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity.
Oh K; Kim S; Park SH; Gu H; Roopenian D; Chung DH; Kim YS; Lee DS
J Immunol; 2005 Feb; 174(4):2030-6. PubMed ID: 15699132
[TBL] [Abstract][Full Text] [Related]
29. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
30. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
31. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
32. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
[TBL] [Abstract][Full Text] [Related]
33. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation.
Zhan Y; Corbett AJ; Brady JL; Sutherland RM; Lew AM
J Immunol; 2000 Oct; 165(7):3612-9. PubMed ID: 11034363
[TBL] [Abstract][Full Text] [Related]
34. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-gamma release by liver NKT cells.
Trobonjaca Z; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 2001 Aug; 167(3):1413-22. PubMed ID: 11466360
[TBL] [Abstract][Full Text] [Related]
35. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
Kawahara M; Takaku H
Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
[TBL] [Abstract][Full Text] [Related]
36. Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.
Hong C; Lee H; Park YK; Shin J; Jung S; Kim H; Hong S; Park SH
Cancer Res; 2009 May; 69(10):4301-8. PubMed ID: 19401453
[TBL] [Abstract][Full Text] [Related]
37. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
38. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
39. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
40. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
